Meloxicam: a selective COX-2 inhibitor non-steroidal anti-inflammatory drug.

摘要: Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible isoform of cyclo-oxygenase (COX)-2 enzyme. This enzyme has major role in mediating inflammatory response, while synthesis prostaglandins required for normal physiological functioning stomach and kidneys under control constitutive isoform, COX-1. Other NSAIDs clinical use show varying degrees selectivity towards Only meloxicam (albeit to lesser extent) nimesulide could be described as selective COX-2. In comparative trials patients with osteo- rheumatoid arthritis, been found at least effective other NSAIDs, but greatly reduced incidence gastrointestinal side-effects. There no evidence causes any deterioration renal function moderate failure, accumulation continued use. Meloxicam's half-life 20 h makes it ideal once daily administration, 99% converted inactive metabolites prior excretion. No clinically significant interactions have detected, making suitable co-existing pathology. safety tolerability make advance treatment rheumatic disease.